title: Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer.
abstract: The sentinel lymph node dissection (SLND) concept relies on the accurate detection of primary nodal landing sites and could represent a major advancement towards accurate, non-invasive pelvic staging in prostate cancer (PCa). Different iterations of the technique have now been validated and reproduced mostly in large-volume centres. The existing evidence denotes the feasibility and sensitivity of SLND, with encouraging pre- and intraoperative detection rates of 98% and 96%. Yet, current surgical practice mandates a backup template dissection due to a false negative rate, up to 7.1%, of tracer-guided surgery. In practice, SLND failed to achieve nodal detection in up to 20% of pelvic sidewalls. Despite scarce validated evidence, current consensus mainly attributes these false negative cases to altered prostatic drainage secondary to malignant obliteration of lymphovascular structures. In parallel, multiple SLND studies have highlighted the complex and variable drainage pathways from the prostate, furthering the established anatomical atlases. The most promising approach may therefore rely in magnetic nanoparticles and PCa-targeting ligands. However, in the absence of a clear sentinel node or region for the prostate, formal SLND is difficult to integrate in routine surgical practice for now. As such, tracer-guided dissection is only used as a complementary intervention to highlight first- echelon nodes and aberrant lymphatic pathways found beyond the commonly adopted pelvic lymphadenectomy templates.
authors: Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, 75013 Paris, France.
authors: Gavish
authors: G
authors: Munbauhal
authors: Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, 75013 Paris, France; Institut Universitaire de Cancérologie, Pierre et Marie Curie, University Paris 6, GRC n 5, CeRePP/ONCOTYPE-URO, 75013 Paris, France.
authors: Thomas
authors: T
authors: Seisen
authors: Department of Urology, CHC Liege, Liège, Belgium.
authors: Florie D
authors: FD
authors: Gomez
authors: Academic Department of Urology, CHU Rennes and University of Rennes, France.
authors: Benoit
authors: B
authors: Peyronnet
authors: Institut Universitaire de Cancérologie, Pierre et Marie Curie, University Paris 6, GRC n 5, CeRePP/ONCOTYPE-URO, 75013 Paris, France; Academic Department of Urology of Tenon, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, 75013 Paris, France.
authors: Olivier
authors: O
authors: Cussenot
authors: Academic Department of Urology and Comprehensive Cancer Centre, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
authors: Shahrokh F
authors: SF
authors: Shariat
authors: Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, 75013 Paris, France; Institut Universitaire de Cancérologie, Pierre et Marie Curie, University Paris 6, GRC n 5, CeRePP/ONCOTYPE-URO, 75013 Paris, France. Electronic address: morgan.roupret@aphp.fr.
authors: Morgan
authors: M
authors: Rouprêt
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods; D008198:Lymph Nodes / Q000473:pathology; D061305:Lymphoscintigraphy; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D019275:Radiopharmaceuticals; D000071036:Sentinel Lymph Node / Q000473:pathology*; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals
keywords: Fluorescence; Indocyanine green; Lymph node excision; Lymphoscintigraphy; Prostatic neoplasms; Radioactive tracers; Sentinel lymph node biopsy